CRP and ankylosing spondylitis: A retrospective analysis of 15 ankylosing spondylitis patients (29.9±6.72 years) with moderate to high disease activity (ASDAS-CRP 3.82±1.47) despite monotherapy with bDMARDs (4 etanercept (ETA), 3 infliximab (IFX), 5 ADA, 3 SEC) for at least 3 months indicated that adding tofacitinib (TOF) 5mg bid was associated with a significant reduction in ASDAS-CRP (1.47 ± 0.48) at 12 weeks of this combination strategy.